Please assess the completion status of the following clinical trial:

Trial Title: Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.~* Subject is 18 to 75 years of age, inclusive.~* Subject has MDD (diagnosed by DSM-IV-TR, and confirmed by the Structured - Clinical Interview for DSM-IV Disorders - Clinical Trial version \[SCID-CT\]).~* Subject is currently experiencing a major depressive episode (diagnosed by DSM IV TR; at least 2 weeks in duration) AND two or three of the following manic symptoms occurring on most days over at least the last 2 weeks (confirmed by the SCID-CT modified for Study D1050304):~  * Elevated, expansive mood~ * Inflated self-esteem or grandiosity~ * More talkative than usual or pressure to keep talking~ * Flight of ideas or subjective experience that thoughts are racing~ * Increase in energy or goal-directed activity (either socially, at work or school, or sexually)~ * Increased or excessive involvement in activities that have a high potential for painful consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)~ * Decreased need for sleep (feeling rested despite sleeping less than usual; to be contrasted from insomnia)~Exclusion Criteria:~* Subject has Axis I or Axis II diagnosis other than MDD that has been the primary focus of treatment within the 3 months prior to screening.~* Subject answers yes to Suicidal Ideation Item 4 or 5 on the C-SSRS (at time of evaluation) at screening or baseline visit.~* Subject has attempted suicide within the past 3 months.~* Subject has a lifetime history of any bipolar I manic or mixed manic episode.~* Subject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone (Type: EXPERIMENTAL): Lurasidone 20, 40 or 60 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).